| Jumlah Saham Beredar | 30,988,420 shares |
| Saham Orang Dalam | 34,264,293 shares |
| Orang Dalam Sejati | 31 |
Skor Sentimen Orang Dalam
Skor Sentimen Orang Dalam mengidentifikasi perusahaan yang dibeli oleh orang dalam korporat.
Ini adalah hasil dari model kuantitatif multifaktor yang canggih yang mengidentifikasi perusahaan dengan tingkat akumulasi internal tertinggi. Model penilaian ini menggunakan kombinasi dari jumlah bersih orang dalam yang membeli dalam 90 hari sebelumnya, total saham yang dibeli sebagai persentase dari jumlah saham yang beredar, dan total saham yang dimiliki oleh orang dalam. Angka tersebut berkisar dari 0 hingga 100, dengan angka yang lebih tinggi menunjukkan tingkat akumulasi yang lebih tinggi dibandingkan dengan perusahaan sejenis, dan 50 adalah rata-rata.
Frekuensi Pembaruan: Setiap Hari
Skor Sentimen Petugas
Skor Sentimen Pejabat menemukan perusahaan yang dibeli oleh Pejabat Korporat.
Menurut definisi, Pejabat Korporasi adalah Orang Dalam Korporasi, tetapi tidak seperti beberapa Orang Dalam lainnya (Pemegang Saham 10% dan Anggota Dewan), Pejabat bekerja untuk perusahaan setiap hari, dan mereka menggunakan uang mereka sendiri saat bertransaksi . (Pemegang Saham 10% dan Anggota Dewan seringkali adalah manajer dana yang mengelola uang orang lain.) Dengan demikian, transaksi orang dalam yang dilakukan oleh Pejabat jauh lebih signifikan dan harus ditangani dengan tepat.
Seperti Skor Sentimen Internal, Skor Sentimen Pejabat adalah hasil dari model kuantitatif multi-faktor yang canggih yang mengidentifikasi perusahaan dengan tingkat akumulasi pejabat tertinggi.
Frekuensi Pembaruan: Setiap Hari
Metrik Utama Orang Dalam
Kartu ini menunjukkan peringkat perusahaan berdasarkan berbagai metrik internal. Peringkat persentil menunjukkan bagaimana perusahaan ini dibandingkan dengan perusahaan lain di pasar AS. Peringkat yang lebih tinggi menunjukkan situasi yang lebih baik.
Sebagai contoh, secara umum diterima bahwa pembelian oleh orang dalam perusahaan adalah indikator positif, sehingga perusahaan dengan lebih banyak pembelian oleh orang dalam akan mendapat peringkat lebih tinggi daripada perusahaan dengan lebih sedikit pembelian oleh orang dalam (atau bahkan penjualan oleh orang dalam).
Jumlah Bersih Pembelian oleh Orang Dalam (Peringkat)
-1 ( )
9888 out of 11323Jumlah Bersih Pembelian oleh Orang Dalam adalah total jumlah orang dalam yang membeli dikurangi total jumlah orang dalam yang menjual dalam 90 hari terakhir. Peringkat persentil ditunjukkan di sini (kisaran dari 0 hingga 100%).
Persentase Saham yang Dibeli oleh Orang Dalam (Peringkat)
-1.243 %( )
11084 out of 11244Persentase Saham yang Dibeli oleh Orang Dalam adalah total jumlah saham yang dibeli oleh orang dalam dikurangi total jumlah saham yang dijual oleh orang dalam dalam 90 hari terakhir, dibagi dengan total jumlah saham yang beredar dan dikalikan dengan 100.
Grafik Perdagangan Orang Dalam
Grafik berikut menunjukkan Skye Bioscience, Inc. transaksi orang dalam. Orang dalam adalah pejabat, direktur, atau investor signifikan dalam suatu perusahaan. Secara umum, melakukan transaksi di perusahaan mereka berdasarkan informasi material yang belum dipublikasikan adalah ilegal bagi orang dalam. Ini tidak berarti bahwa mereka dilarang melakukan transaksi apa pun di perusahaan mereka sendiri. Namun, mereka wajib melaporkan semua transaksi kepada SEC melalui Formulir 4.
Daftar Orang Dalam dan Metrik Profitabilitas
Tabel ini menampilkan daftar orang dalam yang diketahui, dan dibuat secara otomatis dari pengajuan yang diungkapkan kepada SEC. Selain nama, jabatan terbaru, dan sebutan direktur, pejabat, atau pemilik 10%, kami memberikan kepemilikan terbaru yang diungkapkan. Selain itu, jika memungkinkan, kami memberikan kinerja perdagangan historis untuk orang dalam tersebut. Kinerja perdagangan historis adalah rata-rata tertimbang dari kinerja transaksi pembelian pasar terbuka aktual yang dilakukan oleh orang dalam tersebut. Untuk informasi lebih lanjut tentang bagaimana ini dihitung, tonton webinar YouTube ini.
See our leaderboard of most profitable insider traders.
| Orang Dalam | Rata-rata Keuntungan (%) | Saham Dimiliki |
Terbagi Disesuaikan |
|---|---|---|---|
|
5AM Partners VII, LLC
10% Owner -
|
8,224,699 | 8,224,699 | |
| Kaitlyn Melanie Arsenault Chief Financial Officer - [O] | 167,522 | 167,522 | |
| Elizabeth Berecz Chief Financial Officer - [O] | 1,050,000 | 1,050,000 | |
| Douglas A Cesario CFO and Secretary - [O] | 643,501 | 643,501 | |
| Margaret Dalesandro | 400,000 | ||
| Avtar S Dhillon Director - [D] | 0 | 0 | |
| Punit Dhillon Chief Executive Officer, Director - [D] [O] | 329,823 | 329,823 | |
| Tuan Tu Diep Chief Development Officer - [O] | 82,259 | 82,259 | |
|
Emerald Health Sciences Inc.
10% Owner -
|
169,407,901 | 677,632 | |
| Thomas George Director - [D] | 60,000 | 60,000 |
| Orang Dalam | Rata-rata Keuntungan (%) | Saham Dimiliki |
Terbagi Disesuaikan |
|---|---|---|---|
| Grayson Paul A. Director - [D] | 259,701 | 259,701 | |
| James L Heppell Director - [D] | 500,000 | 500,000 | |
| John B Hollister | 200,000 | ||
| Douglas S Ingram Vice Chairman, Director - [D] [O] | 372,500 | 372,500 | |
| Richard Janney | 0 | ||
| Dennis D Kim | 4,736,541 | ||
|
Cosmas N Lykos
Chairman, Director, 10% Owner -
[D]
[O]
|
4,599,400 | 4,599,400 | |
|
Brian D Ladin
10% Owner -
|
249,098 | 249,098 | |
|
Reg Alexander Lapham
10% Owner -
|
3,787,500 | 3,787,500 | |
| Francisco Javier Mendez - | 0 | 0 |
| Orang Dalam | Rata-rata Keuntungan (%) | Saham Dimiliki |
Terbagi Disesuaikan |
|---|---|---|---|
| McLaughlin Gerald W. Director - [D] | 61,250 | 61,250 | |
| Yosbani Mendez - | 2,440 | 2,440 | |
| Brian Stuart Murphy CEO, Chief Medical Officer, Director - [D] [O] | 1,275,000 | 1,275,000 | |
| Sukhwinder Singh Rai Director - [D] | 73,561 | 294 | |
|
Schwab Andrew J.
Director, 10% Owner -
[D]
|
8,224,699 | 8,224,699 | |
|
Squires Richard D.
10% Owner -
|
1,515,000 | 1,515,000 | |
| Praveen Tyle | 275,000 | ||
| Elena Traistaru | 1,000,000 | ||
| Christopher Twitty Chief Scientific Officer - [O] | 162,484 | 162,484 | |
|
Versant Ventures III, LLC
10% Owner -
|
504,872,726 | 2,019,491 | |
| Keith Wayne Ward | 250,000 |
Report errors via our new Insider Auditing Tool
Rekam Jejak Pembelian Orang Dalam - Analisis Keuntungan Jangka Pendek
Pada bagian ini, kami menganalisis profitabilitas setiap pembelian saham oleh orang dalam di pasar terbuka yang tidak direncanakan yang dilakukan di SKYE / Skye Bioscience, Inc.. Analisis ini membantu memahami apakah orang dalam tersebut secara konsisten menghasilkan pengembalian abnormal, dan layak untuk diikuti. Analisis ini dilakukan selama satu tahun setelah setiap transaksi, dan hasilnya bersifat teoretis .
Tabel berikut menunjukkan pembelian pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Ang Adjusted Shares ay ang jumlah saham yang disesuaikan dengan pemisahan saham (stock split).
Rekam Jejak Penjualan Orang Dalam - Analisis Kerugian Jangka Pendek
Dalam bagian ini, kami menganalisis penghindaran kerugian jangka pendek dari setiap penjualan dalam pasar terbuka yang tidak direncanakan oleh orang dalam yang dilakukan di SKYE / Skye Bioscience, Inc.. Pola penghindaran kerugian yang konsisten dapat menunjukkan bahwa transaksi penjualan di masa mendatang dapat memprediksi penurunan harga. Analisis ini berlaku untuk satu tahun setelah setiap perdagangan, dan hasilnya bersifat teoretis .
Tabel berikut menunjukkan penjualan pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Ang Adjusted Shares ay ang jumlah saham yang disesuaikan dengan pemisahan saham (stock split).
Riwayat Transaksi
Klik ikon tautan untuk melihat riwayat transaksi lengkap. Transaksi yang dilaporkan sebagai bagian dari rencana perdagangan otomatis 10b5-1 akan memiliki tanda X di kolom yang bertanda 10b-5.
| Berkas Tanggal |
Perdagangan Tanggal |
Formulir | Orang Dalam | Ticker | Judul Keamanan | Kode | Langsung | Latihan Harga |
Satuan Harga |
Unit Diubah |
Nilai Diubah (1 ribu) |
Sisa Pilihan |
Sisa Saham |
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-08-22 | 2025-08-22 | 4 | Schwab Andrew J. By 5AM Co-Investors II, L.P. | SKYE | Common Stock | I | 3.4200 | -6,470 | -22 | 57,493 | ||||
| 2025-08-22 | 2025-08-22 | 4 | Schwab Andrew J. By 5AM Ventures II, L.P. | SKYE | Common Stock | I | 3.4200 | -163,979 | -561 | 1,457,064 | ||||
| 2025-08-22 | 2025-08-21 | 4 | Schwab Andrew J. By 5AM Co-Investors II, L.P. | SKYE | Common Stock | I | 3.5700 | -2,314 | -8 | 63,963 | ||||
| 2025-08-22 | 2025-08-21 | 4 | Schwab Andrew J. By 5AM Ventures II, L.P. | SKYE | Common Stock | I | 3.5700 | -58,642 | -209 | 1,621,043 | ||||
| 2025-08-22 | 2025-08-22 | 4 | 5AM Partners VII, LLC By 5AM Co-Investors II, L.P. | SKYE | Common Stock | I | 3.4200 | -6,470 | -22 | 57,493 | ||||
| 2025-08-22 | 2025-08-22 | 4 | 5AM Partners VII, LLC By 5AM Ventures II, L.P. | SKYE | Common Stock | I | 3.4200 | -163,979 | -561 | 1,457,064 | ||||
| 2025-08-22 | 2025-08-21 | 4 | 5AM Partners VII, LLC By 5AM Co-Investors II, L.P. | SKYE | Common Stock | I | 3.5700 | -2,314 | -8 | 63,963 | ||||
| 2025-08-22 | 2025-08-21 | 4 | 5AM Partners VII, LLC By 5AM Ventures II, L.P. | SKYE | Common Stock | I | 3.5700 | -58,642 | -209 | 1,621,043 | ||||
| 2025-04-25 | 3 | Twitty Christopher | SKYE | Common Stock | D | 81,242 | ||||||||
| 2025-02-28 | 2024-11-18 | 4/A | Arsenault Kaitlyn Melanie | SKYE | Common Stock | D | 4.9900 | -43,026 | -215 | 167,522 | ||||
| 2025-02-28 | 2024-11-15 | 4/A | Arsenault Kaitlyn Melanie | SKYE | Common Stock | D | 5.5500 | -190 | -1 | 210,548 | ||||
| 2024-11-20 | 2024-11-18 | 4 | Diep Tuan Tu | SKYE | Common Stock | D | 4.9900 | -19,489 | -97 | 82,259 | ||||
| 2024-11-20 | 2024-11-15 | 4 | Diep Tuan Tu | SKYE | Common Stock | D | 5.5500 | -85 | -0 | 101,748 | ||||
| 2024-11-19 | 2024-11-18 | 4 | Arsenault Kaitlyn Melanie | SKYE | Common Stock | D | 4.9900 | -43,206 | -216 | 166,342 | ||||
| 2024-11-19 | 2024-11-15 | 4 | Arsenault Kaitlyn Melanie | SKYE | Common Stock | D | 5.5500 | -190 | -1 | 209,548 | ||||
| 2024-11-19 | 2024-11-18 | 4 | DHILLON PUNIT | SKYE | Common Stock | D | 4.9900 | -82,546 | -412 | 329,823 | ||||
| 2024-11-19 | 2024-11-15 | 4 | DHILLON PUNIT | SKYE | Common Stock | D | 5.5500 | -364 | -2 | 412,369 | ||||
| 2024-11-19 | 2024-11-18 | 4 | Grayson Paul A. | SKYE | Common Stock | D | 4.9900 | -86,244 | -430 | 259,701 | ||||
| 2024-11-19 | 2024-11-15 | 4 | Grayson Paul A. | SKYE | Common Stock | D | 5.5500 | -307 | -2 | 345,945 | ||||
| 2024-09-13 | 2024-09-13 | 4 | Schwab Andrew J. By 5AM Co-Investors II, L.P. | SKYE | Common Stock | I | 6.0600 | -79 | -0 | 66,277 | ||||
| 2024-09-13 | 2024-09-13 | 4 | Schwab Andrew J. By 5AM Ventures II, L.P. | SKYE | Common Stock | I | 6.0600 | -2,000 | -12 | 1,679,685 | ||||
| 2024-09-13 | 2024-09-13 | 4 | Schwab Andrew J. By 5AM Ventures VII, L.P. | SKYE | Common Stock | I | 6.0600 | -11,758 | -71 | 8,167,206 | ||||
| 2024-09-13 | 2024-09-11 | 4 | Schwab Andrew J. By 5AM Co-Investors II, L.P. | SKYE | Common Stock | I | 6.6000 | -1,440 | -10 | 66,356 | ||||
| 2024-09-13 | 2024-09-11 | 4 | Schwab Andrew J. By 5AM Ventures II, L.P. | SKYE | Common Stock | I | 6.6000 | -36,504 | -241 | 1,681,685 | ||||
| 2024-09-13 | 2024-09-11 | 4 | Schwab Andrew J. By 5AM Ventures VII, L.P. | SKYE | Common Stock | I | 6.6000 | -214,556 | -1,416 | 8,178,964 | ||||
| 2024-09-13 | 2024-09-13 | 4 | 5AM Partners VII, LLC By 5AM Co-Investors II, L.P. | SKYE | Common Stock | I | 6.0600 | -79 | -0 | 66,277 | ||||
| 2024-09-13 | 2024-09-13 | 4 | 5AM Partners VII, LLC By 5AM Ventures II, L.P. | SKYE | Common Stock | I | 6.0600 | -2,000 | -12 | 1,679,685 | ||||
| 2024-09-13 | 2024-09-13 | 4 | 5AM Partners VII, LLC By 5AM Ventures VII, L.P. | SKYE | Common Stock | I | 6.0600 | -11,758 | -71 | 8,167,206 | ||||
| 2024-09-13 | 2024-09-11 | 4 | 5AM Partners VII, LLC By 5AM Co-Investors II, L.P. | SKYE | Common Stock | I | 6.6000 | -1,440 | -10 | 66,356 | ||||
| 2024-09-13 | 2024-09-11 | 4 | 5AM Partners VII, LLC By 5AM Ventures II, L.P. | SKYE | Common Stock | I | 6.6000 | -36,504 | -241 | 1,681,685 | ||||
| 2024-09-13 | 2024-09-11 | 4 | 5AM Partners VII, LLC By 5AM Ventures VII, L.P. | SKYE | Common Stock | I | 6.6000 | -214,556 | -1,416 | 8,178,964 | ||||
| 2024-08-27 | 2024-08-26 | 4 | DHILLON PUNIT | SKYE | Common Stock | D | 15,727 | 412,733 | ||||||
| 2024-03-15 | 2024-03-13 | 4 | Schwab Andrew J. By 5AM Ventures VII, L.P. | SKYE | Common Stock | I | 10.0000 | 450,000 | 4,500 | 8,393,520 | ||||
| 2024-03-15 | 2024-03-13 | 4 | 5AM Partners VII, LLC By 5AM Ventures VII, L.P. | SKYE | Common Stock | I | 10.0000 | 450,000 | 4,500 | 8,393,520 | ||||
| 2024-03-04 | 2024-02-29 | 4 | Grayson Paul A. | SKYE | Common Stock | D | 100,000 | 346,252 | ||||||
| 2024-03-04 | 2024-02-29 | 4 | Diep Tuan Tu | SKYE | Common Stock | D | 25,000 | 101,833 | ||||||
| 2024-03-04 | 2024-02-29 | 4/A | Arsenault Kaitlyn Melanie | SKYE | Common Stock | D | 25,000 | 209,738 | ||||||
| 2024-03-04 | 2024-02-29 | 4/A | DHILLON PUNIT | SKYE | Common Stock | D | 100,000 | 397,006 | ||||||
| 2024-03-01 | 2024-02-29 | 4 | Arsenault Kaitlyn Melanie | SKYE | Common Stock | D | 25,000 | 210,738 | ||||||
| 2024-03-01 | 2024-02-29 | 4 | DHILLON PUNIT | SKYE | Common Stock | D | 100,000 | 397,006 | ||||||
| 2024-02-02 | 2024-01-31 | 4 | Schwab Andrew J. By 5AM Ventures VII, L.P. | SKYE | Common Stock | I | 2.3100 | 5,206,074 | 12,026 | 7,943,520 | ||||
| 2024-02-02 | 2024-01-31 | 4 | 5AM Partners VII, LLC By 5AM Ventures VII, L.P. | SKYE | Common Stock | I | 2.3100 | 5,206,074 | 12,026 | 7,943,520 | ||||
| 2023-11-06 | 2023-11-06 | 4 | Grayson Paul A. | SKYE | Common Stock | D | 173,721 | 246,252 | ||||||
| 2023-11-06 | 2023-11-06 | 4 | DHILLON PUNIT | SKYE | Common Stock | D | 194,270 | 297,006 | ||||||
| 2023-11-06 | 2023-11-06 | 4 | Arsenault Kaitlyn Melanie | SKYE | Common Stock | D | 128,209 | 185,738 | ||||||
| 2023-08-31 | 2023-08-29 | 4/A | DHILLON PUNIT | SKYE | Common Stock | D | 0.0187 | 881,000 | 16 | 25,683,957 | ||||
| 2023-08-31 | 2023-08-28 | 4/A | DHILLON PUNIT | SKYE | Common Stock | D | 0.0171 | 110,000 | 2 | 24,802,957 | ||||
| 2023-08-31 | 2023-08-25 | 4/A | DHILLON PUNIT | SKYE | Common Stock | D | 20,277,414 | 24,683,957 | ||||||
| 2023-08-31 | 2023-08-23 | 4/A | DHILLON PUNIT | SKYE | Common Stock | D | 0.0118 | 9,000 | 0 | 24,692,957 | ||||
| 2023-08-29 | 2023-08-29 | 4 | DHILLON PUNIT | SKYE | Common Stock | D | 0.0187 | 881,000 | 16 | 41,554,828 | ||||
| 2023-08-29 | 2023-08-28 | 4 | DHILLON PUNIT | SKYE | Common Stock | D | 0.0171 | 110,000 | 2 | 40,673,828 | ||||
| 2023-08-29 | 2023-08-25 | 4 | DHILLON PUNIT | SKYE | Common Stock | D | 20,277,414 | 40,554,828 | ||||||
| 2023-08-29 | 2023-08-23 | 4 | DHILLON PUNIT | SKYE | Common Stock | D | 0.0118 | 9,000 | 0 | 40,563,828 | ||||
| 2023-08-29 | 2023-08-25 | 4 | Grayson Paul A. | SKYE | Common Stock | D | 18,132,596 | 18,132,596 | ||||||
| 2023-08-29 | 2023-08-25 | 4 | Arsenault Kaitlyn Melanie | SKYE | Common Stock | D | 13,382,118 | 14,382,118 | ||||||
| 2023-08-28 | 3 | 5AM Partners VII, LLC By 5AM Ventures VII, L.P. | SKYE | Common Stock | I | 684,361,447 | ||||||||
| 2023-08-28 | 3 | 5AM Partners VII, LLC By 5AM Ventures II, L.P. | SKYE | Common Stock | I | 429,546,911 | ||||||||
| 2023-08-28 | 3 | 5AM Partners VII, LLC By 5AM Co-Investors II, L.P. | SKYE | Common Stock | I | 16,948,799 | ||||||||
| 2023-08-28 | 3 | Versant Ventures III, LLC By Versant Side Fund III, L.P. | SKYE | Common Stock | I | 2,946,924 | ||||||||
| 2023-08-28 | 3 | Versant Ventures III, LLC By Versant Venture Capital III, L.P. | SKYE | Common Stock | I | 498,978,878 | ||||||||
| 2023-08-22 | 2023-08-18 | 4 | Schwab Andrew J. By 5AM Co-Investors II, L.P. | SKYE | Common Stock | I | 0.0103 | 6,389,921 | 66 | 16,948,799 | ||||
| 2023-08-22 | 2023-08-18 | 4 | Schwab Andrew J. By 5AM Ventures II, L.P. | SKYE | Common Stock | I | 0.0103 | 161,944,872 | 1,668 | 429,546,911 | ||||
| 2023-08-22 | 2023-08-18 | 4 | Schwab Andrew J. By 5AM Ventures VII, L.P. | SKYE | Common Stock | I | 0.0103 | 684,361,447 | 7,049 | 684,361,447 | ||||
| 2023-08-22 | 2023-08-18 | 4 | Schwab Andrew J. By 5AM Co-Investors II, L.P. | SKYE | Common Stock | I | 10,558,878 | 10,558,878 | ||||||
| 2023-08-22 | 2023-08-18 | 4 | Schwab Andrew J. By 5AM Ventures II, L.P. | SKYE | Common Stock | I | 267,602,039 | 267,602,039 | ||||||
| 2023-03-17 | 2023-02-22 | 4 | Emerald Health Sciences Inc. | SKYE | Common Stock | D | 0.0386 | 41,379,164 | 1,597 | 169,407,901 | ||||
| 2023-03-17 | 2023-02-22 | 4 | Emerald Health Sciences Inc. | SKYE | Common Stock | D | 0.0170 | 16,641,486 | 283 | 128,028,737 | ||||
| 2022-11-15 | 2022-11-10 | 4 | DHILLON PUNIT Trust | SKYE | Common Stock | I | 2,335,721 | 2,335,721 | ||||||
| 2022-11-15 | 2022-11-10 | 4 | DHILLON PUNIT | SKYE | Common Stock | D | 1,406,543 | 4,406,543 | ||||||
| 2022-11-15 | 2022-11-10 | 4 | Rai Sukhwinder Singh Shares held by wife of Reporting Person | SKYE | Common Stock | I | 73,561 | 73,561 | ||||||
| 2022-11-15 | 2022-11-10 | 4 | Rai Sukhwinder Singh Trust | SKYE | Common Stock | I | 22,157 | 22,157 | ||||||
| 2022-01-31 | 2020-08-07 | 5 | Emerald Health Sciences Inc. | SKYE | Common Stock | D | 0.1000 | -2,566,666 | -257 | 111,387,251 | ||||
| 2022-01-31 | 2019-03-29 | 5 | Emerald Health Sciences Inc. | SKYE | Multi Draw Credit Facility - T3 | D | 0.40 | 5,354,861 | 5,354,861 | |||||
| 2022-01-31 | 2019-03-29 | 5 | Emerald Health Sciences Inc. | SKYE | Warrants with Credit Facility of Oct 5, 2018 | D | 0.50 | 2,500,000 | 2,500,000 | |||||
| 2022-01-31 | 2019-02-01 | 5 | Emerald Health Sciences Inc. | SKYE | Multi Draw Credit Facility - T2 | D | 0.40 | 38,822 | 38,822 | |||||
| 2022-01-31 | 2019-02-01 | 5 | Emerald Health Sciences Inc. | SKYE | Warrants with Credit Facility of Oct 5, 2018 | D | 0.50 | 2,500,000 | 2,500,000 | |||||
| 2022-01-31 | 2018-11-01 | 5 | Emerald Health Sciences Inc. | SKYE | Warrants with Credit Facility of Oct 5, 2018 | D | 0.50 | 2,500,000 | 2,500,000 | |||||
| 2021-12-16 | 2021-12-14 | 4 | DHILLON PUNIT | SKYE | Stock Option (Right to Buy) | D | 0.06 | 3,090,000 | 3,090,000 | |||||
| 2021-12-16 | 2021-12-14 | 4 | DHILLON PUNIT | SKYE | Common Stock | D | 2,000,000 | 3,000,000 | ||||||
| 2021-12-16 | 2021-12-14 | 4 | Arsenault Kaitlyn Melanie | SKYE | Stock Option (Right to Buy) | D | 0.06 | 1,770,000 | 1,770,000 | |||||
| 2021-12-16 | 2021-12-14 | 4 | Arsenault Kaitlyn Melanie | SKYE | Common Stock | D | 1,000,000 | 1,000,000 | ||||||
| 2021-12-16 | 2021-12-14 | 4 | Ward Keith Wayne | SKYE | Director Option Grant (Right to Buy) | D | 0.06 | 250,000 | 250,000 | |||||
| 2021-10-05 | 2021-10-04 | 4 | Arsenault Kaitlyn Melanie | SKYE | Employee Stock Option (Right to Buy) | D | 0.09 | 1,600,000 | 2,000,000 | |||||
| 2021-09-16 | 2021-09-14 | 4 | DALESANDRO MARGARET | SKYE | Director Stock Option (Right to Buy) | D | 0.12 | 150,000 | 400,000 | |||||
| 2021-09-16 | 2021-09-14 | 4 | HEPPELL JAMES L | SKYE | Director Stock Option (Right to Buy) | D | 0.12 | 150,000 | 1,350,000 | |||||
| 2021-09-16 | 2021-09-14 | 4 | TYLE PRAVEEN | SKYE | Director Stock Option (Right to Buy) | D | 0.12 | 25,000 | 275,000 | |||||
| 2021-07-26 | 2021-07-22 | 4 | TYLE PRAVEEN | SKYE | Director Option Grant (Right to Buy) | D | 0.14 | 250,000 | 250,000 | |||||
| 2020-08-13 | 2020-08-07 | 4/A | Emerald Health Sciences Inc. | EMBI | Common Stock | D | 0.1000 | -2,566,666 | -257 | 123,923,501 | ||||
| 2020-08-12 | 2020-08-07 | 4 | DALESANDRO MARGARET | EMBI | Director Option Grant (Right to Buy) | D | 0.04 | 250,000 | 250,000 | |||||
| 2020-08-11 | 2020-08-07 | 4 | Emerald Health Sciences Inc. | EMBI | Common Stock | D | 0.1000 | -3,000,000 | -300 | 123,490,167 | ||||
| 2020-08-11 | 2020-08-07 | 4 | Traistaru Elena | EMBI | Consultant Option Grant (Right to Buy) | D | 0.04 | 1,000,000 | 1,000,000 | |||||
| 2020-08-11 | 2020-08-07 | 4 | KIM DENNIS D | EMBI | Employee Stock Option (Right to Buy) | D | 0.04 | 4,000,000 | 4,736,541 | |||||
| 2020-08-11 | 2020-08-07 | 4 | HEPPELL JAMES L | EMBI | Director Option Grant (Right to Buy) | D | 0.04 | 1,000,000 | 1,200,000 | |||||
| 2020-08-11 | 2020-08-07 | 4 | HEPPELL JAMES L | EMBI | Common Stock | D | 0.1000 | 500,000 | 50 | 500,000 | ||||
| 2020-08-11 | 2020-08-07 | 4 | DHILLON PUNIT | EMBI | Employee Option Grant (Right to Buy) | D | 0.04 | 9,000,000 | 9,200,000 | |||||
| 2020-08-11 | 2020-08-07 | 4 | DHILLON PUNIT | EMBI | Common Stock | D | 0.1000 | 1,000,000 | 100 | 1,000,000 | ||||
| 2020-01-28 | 2019-12-20 | 4 | Emerald Health Sciences Inc. | EMBI | 7% Convertible Debt | D | 0.40 | 0.4000 | -4,080,000 | -1,632 | 5,036,250 | |||
| 2020-01-28 | 2019-12-20 | 4 | Emerald Health Sciences Inc. | EMBI | Warrant(Right to Buy) | D | 0.10 | 0.1000 | -40,800,000 | -4,080 | 0 | |||
| 2020-01-28 | 2019-12-20 | 4 | Emerald Health Sciences Inc. | EMBI | Common Stock | D | 4,080,000.0000 | 40,800,000 | 166,464,000,000 | 126,490,167 | ||||
| 2020-01-28 | 2019-12-20 | 4 | Emerald Health Sciences Inc. | EMBI | Common Stock | D | 0.1000 | 40,800,000 | 4,080 | 126,490,167 | ||||
| 2019-08-23 | 2019-08-21 | 4 | KIM DENNIS D | EMBI | Employee Stock Options (Right to Buy) | D | 0.30 | 736,541 | 736,541 | |||||
| 2019-04-01 | 2019-03-29 | 4 | Emerald Health Sciences Inc. | EMBI | Warrant (Right to Buy) | D | 0.50 | 2,500,000 | 7,500,000 | |||||
| 2019-04-01 | 2019-03-29 | 4 | Emerald Health Sciences Inc. | EMBI | 7% Convertible Debt | D | 0.40 | 2,000,000.0000 | 2,000,000 | 4,000,000,000 | 6,000,000 | |||
| 2019-02-01 | 2019-02-01 | 4 | Emerald Health Sciences Inc. | NMUS | 7% Convertible Debt | D | 0.40 | 2,500,000 | ||||||
| 2019-02-01 | 2019-02-01 | 4 | Emerald Health Sciences Inc. | NMUS | Warrant (Right to Buy) | D | 0.50 | 2,500,000 | 2,500,000 | |||||
| 2018-12-28 | 2018-12-27 | 4 | Emerald Health Sciences Inc. | NMUS | Common Stock | D | 37,667 | 73,153,917 | ||||||
| 2018-11-01 | 2018-11-01 | 4 | Emerald Health Sciences Inc. | NMUS | Warrant (Right to Buy) | D | 0.50 | 2,500,000 | 2,500,000 | |||||
| 2018-11-01 | 2018-11-01 | 4 | Emerald Health Sciences Inc. | NMUS | 7% Convertible Debt | D | 0.40 | 2,500,000 | ||||||
| 2018-10-12 | 2018-10-10 | 4 | DHILLON AVTAR S | NMUS | Director Stock Option (Right to Buy) | D | 0.30 | 1,000,000 | 1,000,000 | |||||
| 2018-10-12 | 3 | DHILLON AVTAR S | NMUS | No securities are beneficially owned. | D | 0 | ||||||||
| 2018-10-12 | 2018-10-10 | 4 | DHILLON PUNIT | NMUS | Director Stock Option (Right to Buy) | D | 0.30 | 200,000 | 200,000 | |||||
| 2018-10-12 | 2018-10-10 | 4 | HEPPELL JAMES L | NMUS | Director Stock Option (Right to Buy) | D | 0.30 | 200,000 | 200,000 | |||||
| 2018-07-23 | 2018-07-23 | 4 | Cesario Douglas A | NMUS | Employee Stock Option (Right to Buy) | D | 0.24 | 1,195,073 | 1,195,073 | |||||
| 2018-07-23 | 2018-07-23 | 4 | Cesario Douglas A | NMUS | Common Stock | D | 643,501 | 643,501 | ||||||
| 2018-05-31 | 3 | Cesario Douglas A | NMUS | No securities beneficially owned. | D | 0 | ||||||||
| 2018-04-03 | 2018-03-29 | 4 | Emerald Health Sciences Inc. | NMUS | Series F Convertible Preferred Stock | D | 0.10 | -2,000 | 0 | |||||
| 2018-04-03 | 2018-03-29 | 4 | Emerald Health Sciences Inc. | NMUS | Series B Convertible Preferred Stock | D | 0.10 | -1,234 | 0 | |||||
| 2018-04-03 | 2018-03-29 | 4 | Emerald Health Sciences Inc. | NMUS | Common Stock | D | 0.1000 | 20,000,000 | 2,000 | 73,116,250 | ||||
| 2018-04-03 | 2018-03-29 | 4 | Emerald Health Sciences Inc. | NMUS | Common Stock | D | 0.1000 | 12,335,000 | 1,234 | 53,116,250 | ||||
| 2018-03-02 | 2018-01-24 | 4 | Emerald Health Sciences Inc. | NMUS | Common Stock Warrant (Right to Buy) | D | 0.00 | -1,781,250 | 0 | |||||
| 2018-03-02 | 2018-01-24 | 4 | Emerald Health Sciences Inc. | NMUS | Common Stock | D | 0.0010 | 1,781,250 | 2 | 40,781,250 | ||||
| 2018-02-21 | 2018-02-16 | 4 | Emerald Health Sciences Inc. | NMUS | Common Stock Warrants (right to buy) | D | 0.10 | 20,400,000 | 20,400,000 | |||||
| 2018-02-21 | 2018-02-16 | 4 | Emerald Health Sciences Inc. | NMUS | Common Stock | D | 15,000,000 | 39,000,000 | ||||||
| 2018-01-29 | 3 | Emerald Health Sciences Inc. | NMUS | Common Stock | D | 48,000,000 | ||||||||
| 2018-01-29 | 3 | Emerald Health Sciences Inc. | NMUS | Common Stock | D | 48,000,000 | ||||||||
| 2018-01-23 | 3 | DHILLON PUNIT | NMUS | No securities beneficially owned. | D | 0 | ||||||||
| 2018-01-23 | 3 | HEPPELL JAMES L | NMUS | No securities beneficially owned. | D | 0 | ||||||||
| 2018-01-22 | 2018-01-18 | 4 | Berecz Elizabeth | NMUS | Common Stock | D | 700,000 | 1,050,000 | ||||||
| 2018-01-22 | 2018-01-18 | 4 | LYKOS COSMAS N | NMUS | Common Stock | D | 900,000 | 4,599,400 | ||||||
| 2018-01-22 | 2018-01-18 | 4 | Murphy Brian Stuart | NMUS | Common Stock | D | 900,000 | 1,275,000 | ||||||
| 2017-03-28 | 2017-03-13 | 4 | Lapham Reg Alexander | NMUS | Common Stock | D | 1.0000 | -119,700 | -120 | 3,787,500 | ||||
| 2015-10-22 | 2015-10-20 | 4 | Berecz Elizabeth | NMUS | Common Stock | D | 350,000 | 350,000 | ||||||
| 2015-10-22 | 2015-10-20 | 4 | Murphy Brian Stuart | NMUS | Common Stock | D | 375,000 | 375,000 | ||||||
| 2015-10-22 | 2015-10-20 | 4 | McLaughlin Gerald W. | NMUS | Common Stock | D | 30,000 | 61,250 | ||||||
| 2015-10-22 | 2015-10-20 | 4 | LYKOS COSMAS N | NMUS | Common Stock | D | 325,000 | 3,699,400 | ||||||
| 2015-10-22 | 2015-10-20 | 4 | GEORGE THOMAS | NMUS | Common Stock | D | 60,000 | 60,000 | ||||||
| 2015-10-22 | 2015-10-20 | 4 | INGRAM DOUGLAS S | NMUS | Common Stock | D | 60,000 | 372,500 | ||||||
| 2015-08-24 | 2015-08-20 | 4 | McLaughlin Gerald W. | NMUS | Series A Preferred Stock | D | -10,000 | 0 | ||||||
| 2015-08-24 | 2015-08-20 | 4 | McLaughlin Gerald W. | NMUS | Common Stock | D | 31,250 | 31,250 | ||||||
| 2015-08-24 | 2015-08-20 | 4 | INGRAM DOUGLAS S | NMUS | Series A Preferred Stock | D | -100,000 | 0 | ||||||
| 2015-08-24 | 2015-08-20 | 4 | INGRAM DOUGLAS S | NMUS | Common Stock | D | 312,500 | 312,500 | ||||||
| 2015-06-03 | 2015-06-01 | 4 | INGRAM DOUGLAS S | NMUS | Stock Option (Right to Buy) | D | 3.00 | 40,000 | 40,000 | |||||
| 2015-06-02 | 2015-05-29 | 4 | McLaughlin Gerald W. | NMUS | Common Stock Warrant (Right to Buy) | D | 5.00 | 2,000 | 2,000 | |||||
| 2015-06-02 | 2015-05-29 | 4 | McLaughlin Gerald W. | NMUS | Series A Preferred Stock | D | 2.50 | 2.5000 | 10,000 | 25 | 10,000 | |||
| 2015-04-16 | 3 | Squires Richard D. | NMUS | Common Stock | D | 2,985,000 | ||||||||
| 2015-04-16 | 3 | Squires Richard D. See Footnote #1 and #3 | NMUS | Common Stock | I | 1,515,000 | ||||||||
| 2015-04-16 | 3 | Squires Richard D. | NMUS | Common Stock | D | 2,985,000 | ||||||||
| 2015-04-16 | 3 | Squires Richard D. See Footnote #1 and #3 | NMUS | Common Stock | I | 1,515,000 | ||||||||
| 2015-04-10 | 2015-04-10 | 4 | Ladin Brian D See Footnote #1 | NMUS | Common Stock | I | 4.9290 | -11,830 | -58 | 249,098 | ||||
| 2015-04-10 | 2015-04-08 | 4 | Ladin Brian D See Footnote #1 | NMUS | Common Stock | I | 4.7900 | -15,800 | -76 | 260,928 | ||||
| 2015-04-10 | 2015-04-08 | 4 | Ladin Brian D See Footnote #1 | NMUS | Common Stock | I | 4.6910 | -23,000 | -108 | 276,728 | ||||
| 2015-01-12 | 2015-01-09 | 4 | GEORGE THOMAS | NMUS | Stock Option (Right to Buy) | D | 3.00 | 40,000 | 40,000 | |||||
| 2014-12-17 | 3 | Ladin Brian D See Footnote (3) | NMUS | Common Stock | I | 1,560,541 | ||||||||
| 2014-12-17 | 3 | Ladin Brian D See Footnote (2) | NMUS | Common Stock | I | 1,394,268 | ||||||||
| 2014-12-17 | 3 | Ladin Brian D See Footnote (3) | NMUS | Common Stock | I | 1,560,541 | ||||||||
| 2014-12-17 | 3 | Ladin Brian D See Footnote (4) | NMUS | Common Stock | I | 1,423,907 | ||||||||
| 2014-12-17 | 3 | Ladin Brian D See Footnote (4) | NMUS | Common Stock | I | 1,423,907 | ||||||||
| 2014-12-17 | 3 | Ladin Brian D See Footnote (2) | NMUS | Common Stock | I | 1,394,268 | ||||||||
| 2014-12-08 | 2014-12-04 | 4 | McLaughlin Gerald W. | NMUS | Stock Option (Right to Buy) | D | 0.42 | 20,000 | 20,000 | |||||
| 2014-12-08 | 2014-12-04 | 4 | LYKOS COSMAS N | NMUS | Stock Option (Right to Buy) | D | 0.42 | 125,000 | 125,000 | |||||
| 2014-12-08 | 2014-12-04 | 4 | Hollister John B | NMUS | Stock Option (Right to Buy) | D | 0.42 | 200,000 | 200,000 | |||||
| 2014-12-08 | 2014-12-04 | 4 | Hollister John B | NMUS | Stock Option (Right to Buy) | D | 0.42 | 480,000 | 480,000 | |||||
| 2014-12-08 | 2014-12-04 | 4 | Berecz Elizabeth | NMUS | Stock Option (Right to Buy) | D | 0.42 | 150,000 | 150,000 | |||||
| 2014-12-08 | 2014-12-04 | 4 | Berecz Elizabeth | NMUS | Stock Option (Right to Buy) | D | 0.42 | 100,000 | 100,000 | |||||
| 2014-12-08 | 2014-12-04 | 4 | Murphy Brian Stuart | NMUS | Stock Option (Right to Buy) | D | 0.42 | 175,000 | 175,000 | |||||
| 2014-12-08 | 2014-12-04 | 4 | Murphy Brian Stuart | NMUS | Stock Option (Right to Buy) | D | 0.42 | 480,000 | 480,000 | |||||
| 2014-11-10 | 2014-10-31 | 4/A | MENDEZ FRANCISCO JAVIER | LGLRD | Common Stock | D | -1,180,000 | 0 | ||||||
| 2014-11-10 | 3 | Lapham Reg Alexander | LGLRD | Common Stock | D | 7,814,400 | ||||||||
| 2014-11-10 | 3 | Lapham Reg Alexander | LGLRD | Common Stock | D | 7,814,400 | ||||||||
| 2014-11-10 | 3 | LYKOS COSMAS N | LGLRD | Common Stock | D | 6,748,800 | ||||||||
| 2014-11-10 | 3 | LYKOS COSMAS N | LGLRD | Common Stock | D | 6,748,800 | ||||||||
| 2014-11-10 | 2014-10-31 | 4 | Mendez Yosbani | LGLRD | Common Stock | D | -4,251,460 | 2,440 | ||||||
| 2014-11-10 | 2014-10-31 | 4 | MENDEZ FRANCISCO JAVIER | LGLR | Common Stock | D | -500,000 | 0 | ||||||
| 2014-01-29 | 3 | Mendez Yosbani | N/A | Common Stock | D | 1,802,500 | ||||||||
| 2014-01-29 | 3 | MENDEZ FRANCISCO JAVIER | N/A | Common Stock | D | 500,000 |
P
Pembelian sekuritas non-derivatif atau derivatif di pasar terbuka atau secara pribadi.
S
Penjualan terbuka atau penjualan pribadi atas sekuritas non-derivatif atau derivatif.
A
Hibah, penghargaan, atau perolehan sekuritas lainnya dari perusahaan (seperti opsi)
C
Konversi turunan
D
Penjualan atau pengalihan sekuritas kembali ke perusahaan.
F
Pembayaran harga pelaksanaan atau kewajiban pajak menggunakan sebagian sekuritas yang diterima dari perusahaan.
G
Pemberian sekuritas oleh atau kepada orang dalam.
K
Swap ekuitas dan transaksi lindung nilai serupa
M
Pelaksanaan atau konversi sekuritas derivatif yang diterima dari perusahaan (seperti opsi)
V
Transaksi yang dilaporkan secara sukarela pada Formulir 4.
J
Lainnya (disertai dengan catatan kaki yang menjelaskan transaksi tersebut)
